Various TLR4 modulators, such as EB05 (NCT04401475), Eritoran (NCT02735707), Naltrexone [90] (NCT04604704, NCT04604678), Curcumin [91] (NCT04382040), and Berberine [92,93,94] (NCT04479202) are undergoing clinical trials for COVID-19. The gene discussed is TLR4; the disease is COVID-19.